Artemis Investment Management LLP maintained its stake in shares of Idexx Laboratories Inc. (NASDAQ:IDXX) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,524 shares of the company’s stock at the end of the second quarter. Artemis Investment Management LLP’s holdings in Idexx Laboratories were worth $2,834,000 as of its most recent filing with the SEC.
Other hedge funds have also modified their holdings of the company. Norges Bank acquired a new stake in shares of Idexx Laboratories during the fourth quarter valued at approximately $59,478,000. First Manhattan Co. boosted its position in Idexx Laboratories by 2,786.9% in the first quarter. First Manhattan Co. now owns 3,522 shares of the company’s stock valued at $275,000 after buying an additional 3,400 shares during the last quarter. Commonwealth Equity Services Inc boosted its position in Idexx Laboratories by 4.1% in the first quarter. Commonwealth Equity Services Inc now owns 19,426 shares of the company’s stock valued at $1,521,000 after buying an additional 770 shares during the last quarter. Aperio Group LLC boosted its position in Idexx Laboratories by 13.0% in the first quarter. Aperio Group LLC now owns 19,738 shares of the company’s stock valued at $1,546,000 after buying an additional 2,265 shares during the last quarter. Finally, Nisa Investment Advisors L.L.C. boosted its position in Idexx Laboratories by 1.9% in the first quarter. Nisa Investment Advisors L.L.C. now owns 68,120 shares of the company’s stock valued at $5,335,000 after buying an additional 1,300 shares during the last quarter. Institutional investors and hedge funds own 91.58% of the company’s stock.
Shares of Idexx Laboratories Inc. (NASDAQ:IDXX) traded down 1.36% during trading on Thursday, reaching $111.87. The company had a trading volume of 369,505 shares. Idexx Laboratories Inc. has a 1-year low of $63.48 and a 1-year high of $115.06. The stock has a market capitalization of $10.02 billion, a price-to-earnings ratio of 50.71 and a beta of 0.56. The company’s 50 day moving average is $111.50 and its 200-day moving average is $93.73.
Idexx Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, August 2nd. The company reported $0.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.12. Idexx Laboratories had a net margin of 11.94% and a negative return on equity of 414.67%. The business had revenue of $467 million for the quarter, compared to analyst estimates of $444.83 million. During the same period in the prior year, the company posted $0.60 EPS. The company’s revenue for the quarter was up 12.9% on a year-over-year basis. On average, equities research analysts anticipate that Idexx Laboratories Inc. will post $2.36 earnings per share for the current year.
IDXX has been the topic of several research analyst reports. Zacks Investment Research cut Idexx Laboratories from a “buy” rating to a “hold” rating in a report on Monday, July 4th. Canaccord Genuity increased their price target on Idexx Laboratories from $90.00 to $98.00 and gave the company a “buy” rating in a report on Wednesday, July 20th. Northcoast Research raised Idexx Laboratories from a “sell” rating to a “neutral” rating in a report on Wednesday, August 3rd. Stifel Nicolaus reissued a “buy” rating and set a $120.00 price target (up from $92.00) on shares of Idexx Laboratories in a report on Wednesday, August 3rd. Finally, Bank of America Corp. initiated coverage on Idexx Laboratories in a report on Thursday. They set a “neutral” rating on the stock. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Idexx Laboratories presently has an average rating of “Buy” and an average price target of $105.20.
In related news, Director Rebecca M. Henderson sold 9,924 shares of the firm’s stock in a transaction dated Thursday, August 25th. The shares were sold at an average price of $110.43, for a total value of $1,095,907.32. Following the transaction, the director now directly owns 16,678 shares of the company’s stock, valued at approximately $1,841,751.54. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Chairman Jonathan W. Ayers sold 60,000 shares of the firm’s stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $107.69, for a total transaction of $6,461,400.00. The disclosure for this sale can be found here. Insiders own 2.79% of the company’s stock.
About Idexx Laboratories
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Idexx Laboratories Inc. (NASDAQ:IDXX).
Receive News & Ratings for Idexx Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idexx Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.